11 assets in Paraganglioma

Therapeutic assets addressing Paraganglioma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Oxodotreotide Paraganglioma	Fundación de investigación HM	P2	B (60)
Ipilimumab Paraganglioma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Paraganglioma	National Cancer Institute (NCI)	P2	CCC (53)
Pembrolizumab Paraganglioma	M.D. Anderson Cancer Center	P2	CCC (53)
Talazoparib Paraganglioma	National Cancer Institute (NCI)	P2	CCC (53)
Olaparib Paraganglioma	Fundación de investigación HM	P1/2	CC (47)
Autologous Anti-Cd19 Car-Expressing T Lymphocytes Paraganglioma	Anusha Kalbasi	P1	CC (43)
Cyclophosphamide Paraganglioma	Anusha Kalbasi	P1	CC (43)
Fludarabine Paraganglioma	Anusha Kalbasi	P1	CC (43)
Fludeoxyglucose Paraganglioma	Anusha Kalbasi	P1	CC (43)
il13ralpha2-specific hinge-optimized 4-1bb-co-stimulatory car/truncated cd19-expressing autologous tn/mem cells Paraganglioma	Anusha Kalbasi	P1	CC (43)